{"acquisitions":[],"changes":[{"companyHref":"/c/kailera-com","date":"2026-10-03","documentUrl":"https://atlasventure.com/portfolio/","domain":"kailera.com","fact":"provenance:existence","name":"Kailera Therapeutics","new":{"publisher":"Atlas Venture","status":"sourced","url":"https://atlasventure.com/portfolio/"},"old":{"publisher":"kailera.com","status":"self-reported","url":"https://kailera.com"},"publisher":"Atlas Venture","reason":null,"retrievedAt":"2026-10-03","slug":"kailera-com","status":"sourced","url":"https://whoraisedwhat.com/c/kailera-com"},{"companyHref":"/c/kailera-com","date":"2026-09-30","documentUrl":"https://atlasventure.com/portfolio/","domain":"kailera.com","fact":"provenance:investor:atlas-venture","name":"Kailera Therapeutics","new":{"publisher":"Atlas Venture","status":"sourced","url":"https://atlasventure.com/portfolio/"},"old":{"publisher":null,"status":"unknown","url":null},"publisher":"Atlas Venture","reason":null,"retrievedAt":"2026-09-30","slug":"kailera-com","status":"sourced","url":"https://whoraisedwhat.com/c/kailera-com"},{"companyHref":"/c/kailera-com","date":"2026-09-30","documentUrl":"https://www.globenewswire.com/news-release/2025/10/14/3165992/0/en/kailera-therapeutics-announces-600-million-series-b-financing-to-further-advance-pipeline-of-next-generation-therapies-for-the-treatment-of-obesity.html","domain":"kailera.com","fact":"provenance:investor:atlas-venture:participant","name":"Kailera Therapeutics","new":{"publisher":"GlobeNewswire","status":"sourced","url":"https://www.globenewswire.com/news-release/2025/10/14/3165992/0/en/kailera-therapeutics-announces-600-million-series-b-financing-to-further-advance-pipeline-of-next-generation-therapies-for-the-treatment-of-obesity.html"},"old":{"publisher":null,"status":"unknown","url":null},"publisher":"GlobeNewswire","reason":null,"retrievedAt":"2026-09-30","slug":"kailera-com","status":"sourced","url":"https://whoraisedwhat.com/c/kailera-com"}],"country":"US","description":"Kailera Therapeutics is a clinical-stage biotech advancing GLP-1, GIP, and amylin agonist drug candidates for obesity. The customer base is patients with chronic weight-related metabolic disease. Backed by Bain Capital Life Sciences and others, Kailera ran a Phase 3 program for KAI-9531 in adults with obesity.","domain":"kailera.com","employees":null,"founded":2023,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":["atlas-venture"],"lat":42.376238,"lng":-71.235564,"location":"San Diego, US","multiples":[],"name":"Kailera Therapeutics","nameSource":{"publisher":"Atlas Venture","retrievedAt":"2026-10-03","status":"sourced","url":"https://atlasventure.com/portfolio/"},"people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":600000000,"connectionsAmong":[],"currency":"USD","date":"2025-10-01","investments":[],"investors":["atlas-venture"],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"kailera-com-2025-10-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-23","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"kailera-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-23","status":"attributed","url":null},{"fact":"existence","publisher":"Atlas Venture","retrievedAt":"2026-10-03","status":"sourced","url":"https://atlasventure.com/portfolio/"},{"fact":"description","publisher":"kailera.com","retrievedAt":"2026-10-03","status":"self-reported","url":"https://kailera.com"},{"fact":"investor:atlas-venture","publisher":"Atlas Venture","retrievedAt":"2026-09-30","status":"sourced","url":"https://atlasventure.com/portfolio/"},{"fact":"investor:atlas-venture:participant","publisher":"GlobeNewswire","retrievedAt":"2026-09-30","status":"sourced","url":"https://www.globenewswire.com/news-release/2025/10/14/3165992/0/en/kailera-therapeutics-announces-600-million-series-b-financing-to-further-advance-pipeline-of-next-generation-therapies-for-the-treatment-of-obesity.html"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[{"id":"investor:{\"actorKind\": \"investor\", \"name\": \"Atlas Venture\", \"role\": \"invested\", \"roundDate\": \"2025-10-01\", \"roundSlug\": \"kailera-com-2025-10-01-series-b\", \"roundType\": \"Series B\", \"slug\": \"atlas-venture\", \"sources\": [{\"publisher\": \"GlobeNewswire\", \"retrievedAt\": \"2026-09-30\", \"status\": \"sourced\", \"url\": \"https://www.globenewswire.com/news-release/2025/10/14/3165992/0/en/kailera-therapeutics-announces-600-million-series-b-financing-to-further-advance-pipeline-of-next-generation-therapies-for-the-treatment-of-obesity.html\"}]}","kind":"investor","sources":[{"publisher":"GlobeNewswire","retrievedAt":"2026-09-30","status":"sourced","url":"https://www.globenewswire.com/news-release/2025/10/14/3165992/0/en/kailera-therapeutics-announces-600-million-series-b-financing-to-further-advance-pipeline-of-next-generation-therapies-for-the-treatment-of-obesity.html"}],"text":"Atlas Venture invested in the 2025-10-01 Series B round."},{"id":"investor:{\"actorKind\": \"investor\", \"name\": \"Atlas Venture\", \"role\": \"portfolio\", \"slug\": \"atlas-venture\", \"sources\": [{\"publisher\": \"Atlas Venture\", \"retrievedAt\": \"2026-09-30\", \"status\": \"sourced\", \"url\": \"https://atlasventure.com/portfolio/\"}]}","kind":"investor","sources":[{"publisher":"Atlas Venture","retrievedAt":"2026-09-30","status":"sourced","url":"https://atlasventure.com/portfolio/"}],"text":"Kailera Therapeutics was listed in Atlas Venture's portfolio, recorded 2026-09-30."}],"generatedAt":"2026-11-09","investors":[{"actorKind":"investor","name":"Atlas Venture","role":"invested","roundDate":"2025-10-01","roundSlug":"kailera-com-2025-10-01-series-b","roundType":"Series B","slug":"atlas-venture","sources":[{"publisher":"GlobeNewswire","retrievedAt":"2026-09-30","status":"sourced","url":"https://www.globenewswire.com/news-release/2025/10/14/3165992/0/en/kailera-therapeutics-announces-600-million-series-b-financing-to-further-advance-pipeline-of-next-generation-therapies-for-the-treatment-of-obesity.html"}]},{"actorKind":"investor","name":"Atlas Venture","role":"portfolio","slug":"atlas-venture","sources":[{"publisher":"Atlas Venture","retrievedAt":"2026-09-30","status":"sourced","url":"https://atlasventure.com/portfolio/"}]}],"state":"insufficient-evidence","tldr":[]},"techStack":["Cloudflare","WordPress","Magnific Popup","Yoast SEO 27.4","reCAPTCHA","Google Analytics","Google Tag Manager","FitVids.JS 1778785549","Font Awesome","ScrollMagic 2.0.7","jQuery Migrate","jQuery Mobile"],"totalRaisedUsd":600000000,"traction":[],"updatedAt":"2026-10-03","valuations":[]}